Citations

Showing 10 of 108162 citations.

White Paper on Ophthalmic Imaging for Choroidal Nevus Identification and Transformation into Melanoma
Lally, Sara E. , Pellegrini, Marco , Kaliki, Swathi , Gündüz, Kaan , Fung, Adrian T. , Duker, Jay S. , Selig, Sara , Yaghy, Antonio , Ferenczy, S , Eydelman, Malvina, Blumenkranz, Mark S. , Shields, Carol L. , Dalvin, Lauren A. , Sagoo, Mandeep S. , Furuta, Minoru , Mruthyunjaya, Prithvi

Mayo Clinic

Translational Vision Science & Technology | February 20, 2021 | Volume: 10 | Issue: 2 | Pages: 24

10.1167/tvst.10.2.24 | PMID 34003909 Get It

Systematic review of outcomes and endpoints in preventive migraine clinical trials
McGinley, James S., Nishida, Tracy K., Buse, Dawn C. , Goadsby, Peter J. , Goadsby, Peter J , Houts, Carrie R. , Lipton, Richard B. , Dodick, David W. , Wirth, Robert J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 20, 2021 | Volume: 61 | Issue: 2 | Pages: 253-262

10.1111/head.14069 | PMID 33600610 Get It

Abstract Background Over the last six decades (earliest included publication from 1959), clinical trials of migraine preventive treatments have led to the regulatory approval of many medications and devices. Despite similar clinical goals, the outcomes and endpoints used in these trials are broad and not well standardized. Objective To describe results from a systematic literature review focused on outcomes and endpoints used in preventive migraine clinical trials. Method A systematic literature review, following a pre‐specified (unregistered) protocol developed to adhere to recommendations of the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses, was conducted to characterize the endpoints and outcomes used in preventive migraine clinical trials. Predetermined terms were searched in PubMed on October 28, 2019. Data related to trial design, subject characteristics, outcomes, and endpoints reported in each publication were extracted. Descriptive summaries of these features were tabulated for the recent subset of publications, published during or after 1988, that were randomized, blinded, and focused on pharmacological or device therapies for the preventive treatment of migraine. Results The initial literature search identified 1506 publications, of which 757 publications were eligible for data extraction. Of specific clinical interest were the recent subset of 268 articles (268/757, 35.4%) fulfilling the targeted criteria. Results showed that the outcomes used to define endpoints varied substantially across publications. For example, in the recent subset of publications, 68.7% (184/268) of the publications examined ≥1 migraine‐specific outcome, 39.6% (106/268) examined ≥1 headache‐specific outcome, 50.7% (136/268) examined ≥1 acute/rescue medication use outcome, 40.3% (108/268) examined ≥1 headache‐related patient‐reported outcome measure (PROM), and 22.0% (59/268) examined ≥1 non‐headache‐specific PROM. Furthermore, the definition of the endpoints used (e.g., change from baseline, fixed timepoint comparisons, categorization of “responders” to treatment based on wide variety of “responder definitions”) also differed across publications. Conclusion Publications from clinical trials of preventive migraine pharmacologic and device treatments differed in terms of study design, endpoint definitions, and how endpoints and outcomes were measured. Although there were common outcomes and endpoints used across publications, no clear “standardized” set of endpoints and outcomes emerged. The inconsistencies in endpoints and outcomes within this literature suggest that the development of a uniform set of outcomes and endpoints could improve the clinical meaningfulness of clinical trial results, facilitate cross‐trial comparisons and better inform patient care. This standard set of outcomes and endpoints should be statistically robust and informed by the priorities of various stakeholders, most importantly, the needs and preferences of people living with migraine.
Seizures and memory impairment induced by patient‐derived anti‐N‐methyl‐D‐aspartate receptor antibodies in mice are attenuated by anakinra, an interleukin‐1 receptor antagonist
Taraschenko, Olga , Ζεκερίδου, Αναστασία , Pittock, Sean J. , Eldridge, Ember, Farukhuddin, FNU , Al‐Saleem, Fetweh H., Kattala, Chandana Devi , Casale, George P. , Willcockson, Gregory, Pittock, S J , Fox, Howard S. , Dessain, Scott K. , Dingledine, Raymond

Mayo Clinic

Epilepsia | February 20, 2021 | Volume: 62 | Issue: 3 | Pages: 671-682

10.1111/epi.16838 | PMID 33596332 Get It

AbstractObjectiveNeuroinflammation associated with anti‐N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis may facilitate seizures. We previously showed that intraventricular administration of cerebrospinal fluid from patients with anti‐NMDAR encephalitis to mice precipitates seizures, thereby confirming that antibodies are directly pathogenic. To determine whether interleukin (IL)‐1‐mediated inflammation exacerbates autoimmune seizures, we asked whether blocking the effects of IL‐1 by anakinra, a selective IL‐1 receptor antagonist, blunts antibody‐induced seizures.MethodsWe infused C57BL/6 mice intraventricularly with purified serum IgG from patients with anti‐NMDAR encephalitis or monoclonal anti‐NMDAR IgG; subdural electroencephalogram was continuously recorded. After a 6‐day interval, mice received anakinra (25 mg/kg sc, twice daily) or vehicle for 5 days. Following a 4‐day washout period, we performed behavioral tests to assess motor function, anxiety, and memory, followed by hippocampus tissue analysis to assess astrocytic (glial fibrillary acidic protein [GFAP]) and microglial (ionized calcium‐binding adapter molecule [Iba]‐1) activation.ResultsOf 31 mice infused with purified patient NMDAR‐IgG (n = 17) or monoclonal NMDAR‐IgG (n = 14), 81% developed seizures. Median baseline daily seizure count during exposure to antibodies was 3.9; most seizures were electrographic. Median duration of seizures during the baseline was 82.5 s. Anakinra administration attenuated daily seizure frequency by 60% (p = .02). Anakinra reduced seizure duration; however, the effect was delayed and became apparent only after the cessation of treatment (p = .04). Anakinra improved novel object recognition in mice with antibody‐induced seizures (p = .03) but did not alter other behaviors. Anakinra reduced the expression of GFAP and Iba‐1 in the hippocampus of mice with seizures, indicating decreased astrocytic and microglial activation.SignificanceOur evidence supports a role for IL‐1 in the pathogenesis of seizures in anti‐NMDAR encephalitis. These data are consistent with therapeutic effects of anakinra in other severe autoimmune and inflammatory seizure syndromes. Targeting inflammation via blocking IL‐1 receptor‐mediated signaling may be promising for developing novel treatments for refractory autoimmune seizures.
Assessing the utility and attitudes toward molecular testing in neuro-oncology: a survey of the Society for Neuro-Oncology members
Ensign, Shannon P. Fortin , Hrachova, Maya , Chang, Susan M. , Mrugała, Maciej M. , Ensign, Shannon P. Fortin

Mayo Clinic

Neuro-Oncology Practice | February 20, 2021 | Volume: 8 | Issue: 3 | Pages: 310-316

10.1093/nop/npab003 | PMID 34055378 Get It

AbstractBackgroundMolecular testing (MT) is utilized in neuro-oncology with increasing frequency. The aim of this study was to determine clinical practice patterns to acquire this information, interpret and utilize MT for patient care, and identify unmet needs in the practical clinical application of MT.MethodsWe conducted a voluntary online survey of providers within the Society for Neuro-Oncology (SNO) membership database between March and April 2019.ResultsWe received 152 responses out of 2022 SNO members (7.5% of membership). 88.8% of respondents routinely order MT for newly diagnosed gliomas. Of those who do not, testing is preferentially performed in younger patients or those with midline tumors. 82.8% use MT in recurrent gliomas. Other common indications included: metastatic tumors, meningioma, and medulloblastoma. Many providers utilize more than one resource (36.0%), most frequently using in-house (41.8%) over commercially available panels. 78.1% used the results for clinical decision-making, with BRAF, EGFR, ALK, and H3K27 mutations most commonly directing treatment decisions. Approximately, half (48.5%) of respondents have molecular tumor boards at their institutions. Respondents would like to see SNO-endorsed guidelines on MT, organized lists of targeted agents available for specific mutations, a database of targetable mutations and clinical trials, and more educational programs on MT.ConclusionThis survey was marked by several limitations including response rate and interpretation of MT. Among respondents, there is routine use of MT in Neuro-Oncology, however, there remains a need for increased guidance for providers to effectively incorporate the expanding genomic data resulting from MT into daily Neuro-Oncology practice.
SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors
Vrana, Julie A. , Terra, Simone , Jenkins, Sarah M. , Mansfield, Aaron S. , Molina, Julian R. , Cassivi, Stephen D. , Roden, Anja C. , Terra, Simone B S P , Mansfield, Aaron S , Cassivi, Stephen D , Boland, Jennifer M. , Xie, Hao

Mayo Clinic

American Journal of Clinical Pathology | February 20, 2021 | Volume: 156 | Issue: 5 | Pages: 853-865

10.1093/ajcp/aqab038 | PMID 33978159 Get It

Abstract Objectives To evaluate SATB2 expression and prognostic implications in a large cohort of thoracic neuroendocrine tumors. Methods Surgical pathology files (1995-2017) and an institutional thymic epithelial tumor database (2010-2020) were searched for resected neuroendocrine tumors. Cases were stained with SATB2 (clone EP281). Percent SATB2-positive tumor cells and expression intensity were scored. Results In the lung, SATB2 was expressed in 5% or more of tumor cells in 29 (74.4%) of 39 small cell carcinomas and 9 (22.5%) of 40 atypical and 26 (40.6%) of 64 typical carcinoid tumors. SATB2 percent tumor cell expression and intensity were higher in small cell carcinomas than in carcinoid tumors (both P < .001, respectively). After adjusting for tumor subtype, SATB2 expression did not correlate with outcome. In the thymus, four (100%) of four atypical carcinoid tumors and one large cell neuroendocrine carcinoma but no small cell carcinoma (n = 2) expressed SATB2 in 5% or more of tumor cells. Conclusions SATB2 (clone EP281) is expressed in a large subset of pulmonary and thymic neuroendocrine tumors and therefore does not appear to be a useful marker to identify the origin of neuroendocrine tumors. Validation studies are needed, specifically including thymic neuroendocrine tumors, as the expression pattern might be different in those tumors.
Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg
Li, Jingen , Gao, Xiang , Ju, Jianqing, Lin, Qian , Karim, Shahid , Xu, Hao , Zhang, Lijing , Mohamed, Essa A. , Somers, Virend K. , Chen, Zhuo , Li, Jingen

Mayo Clinic

JAMA Network Open | February 20, 2021 | Volume: 4 | Issue: 2 | Pages: e2037554

10.1001/jamanetworkopen.2020.37554 | PMID 33595663 Get It

Revisiting and Implementing the Weber and Ventilatory Functional Classifications in Heart Failure by Cardiopulmonary Imaging Phenotyping
Metra, Marco , Losito, Maurizio, Alfonzetti, Eleonora, Boveri, Sara , Sugimoto, Tadafumi , Borlaug, Barry, Metra, Marco , Guazzi, Marco , Borlaug, Barry A. , Bandera, Francesco

Mayo Clinic

Journal of the American Heart Association | February 20, 2021 | Volume: 10 | Issue: 5 | Pages: No page available

10.1161/jaha.120.018822 | PMID 33615821 Get It

Background In heart failure, the exercise gas exchange Weber (A to D) and ventilatory classifications (VC‐1 to VC‐4) historically define disease severity and prognosis. However, their applications in the modern heart failure population of any left ventricular ejection fraction combined with hemodynamics are undefined. We aimed at revisiting and implementing these classifications by cardiopulmonary exercise testing imaging. Methods and Results 269 patients with heart failure with reduced (n=105), mid‐range (n=88) and preserved (n=76) ejection fraction underwent cardiopulmonary exercise testing imaging, primarily assessing the cardiac output (CO), mitral regurgitation, and mean pulmonary arterial pressure (mPAP)/CO slope. Within both classes, a progressively lower exercise CO, higher mPAP/CO slopes, and mitral regurgitation ( P <0.01 all) were observed. After adjustment for age and sex, Cox proportional hazard regression analyses showed that Weber (hazard ratio [HR], 2.9; 95% CI, 1.8–4.7; P <0.001) and ventilatory classes (HR, 1.4; 95% CI, 1.1–2.0; P =0.017) were independently associated with outcome. The best stratification was observed when combining Weber (A/B or C/D) with severe ventilation inefficiency (VC‐4) (HR, 2.7; 95% CI, 1.6–4.8; P <0.001). At multivariable analysis the best hemodynamic determinants of peak oxygen consumption and ventilation to carbon dioxide production slope were CO (β‐coefficient, 0.72±0.16; P <0.001) and mPAP/CO slope (β‐coefficient, 0.72±0.16; P <0.001), respectively. Conclusions In the contemporary heart failure population, the Weber and ventilatory classifications maintain their prognostic ability, especially when combined. Exercise CO and mPAP/CO slope are the best predictors of peak oxygen consumption and ventilation to carbon dioxide production slope classifications representing the main targets of interventions to impact functional class and, likely, event rate.
Feasibility of using megavoltage computed tomography to reduce proton range uncertainty: A simulation study
Hu, Yanle , Ding, Xiaoning, Shen, Jiajian , Liu, Wei , Kang, Yixiu, Yu, Lifeng , Bues, Martin , Liu, Wei , Shen, Jiajian , Leng, Shuai , Yu, Lifeng

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 20, 2021 | Volume: 22 | Issue: 3 | Pages: 131-140

10.1002/acm2.13191 | PMID 33608992 Get It

AbstractPurposeTo demonstrate that variation in chemical composition has a negligible effect on the mapping curve from relative electron density (RED) to proton stopping power ratio (SPR), and to establish the theoretical framework of using Megavoltage (MV) computed tomography (CT), instead of kilovoltage (kV) dual energy CT, to accurately estimate proton SPR.MethodsA simulation study was performed to evaluate the effect of chemical composition variation on kVCT number and proton SPR. The simulation study involved both reference and simulated human tissues. The reference human tissues, together with their physical densities and chemical compositions, came from the ICRP publication 23. The simulated human tissues were created from the reference human tissues assuming that elemental percentage weight followed a Gaussian distribution. For all tissues, kVCT number and proton SPR were obtained through (a) theoretical calculation from tissue’s physical density and chemical composition which served as the ground truth, and (b) estimation from RED using the calibration curves established from the stoichiometric method. Deviations of the estimated values from the calculated values were quantified as errors in using RED to estimate kVCT number and proton SPR.ResultsGiven a chemical composition variation of 5% (1σ) of the nominal percentage weights, the total estimation error of using RED to estimate kVCT number was 0.34%, 0.62%, and 0.77% and the total estimation error of using RED to estimate proton SPR was 0.30%, 0.22%, and 0.16% for fat tissues, non‐fat soft tissues and bone tissues, respectively.ConclusionChemical composition had a negligible effect on the method of using RED to determine proton SPR. RED itself is sufficient to accurately determine proton SPR. MVCT number maintains a superb linear relationship with RED because it is highly dominated by Compton scattering. Therefore, MVCT has great potential in reducing the proton range uncertainty.
Diagnostic Value of 16S Ribosomal RNA Gene Polymerase Chain Reaction/Sanger Sequencing in Clinical Practice
Fida, Madiha , Khalil, Sarwat , Saleh, Omar Abu , Yang, Joshua N., Pritt, Bobbi S. , Patel, Robin , Abu Saleh, Omar , Challener, Douglas W. , Patel, Robin , Fida, Madiha , Pritt, Bobbi S , Sohail, M. Rizwan , Schuetz, Audrey N.

Mayo Clinic

Clinical Infectious Diseases | February 20, 2021 | Volume: 73 | Issue: 6 | Pages: 961-968

10.1093/cid/ciab167 | PMID 34407178 Get It

Abstract Background Accurate microbiologic diagnosis is important for appropriate management of infectious diseases. Sequencing-based molecular diagnostics are increasingly used for precision diagnosis of infections. However, their clinical utility is unclear. Methods We conducted a retrospective analysis of specimens that underwent 16S ribosomal RNA (rRNA) gene polymerase chain reaction (PCR) followed by Sanger sequencing at our institution from April 2017 through March 2019. Results A total of 566 specimens obtained from 460 patients were studied. Patients were considered clinically infected or noninfected based on final diagnosis and management. In 17% of patients, 16S rRNA PCR/sequencing was positive and in 5% of patients, this test led to an impact on clinical care. In comparison, bacterial cultures were positive in 21% of patients. Specimens with a positive Gram stain had 12 times greater odds of having a positive molecular result than those with a negative Gram stain (95% confidence interval for odds ratio, 5.2–31.4). Overall, PCR positivity was higher in cardiovascular specimens (37%) obtained from clinically infected patients, with bacterial cultures being more likely to be positive for musculoskeletal specimens (P &lt; .001). 16S rRNA PCR/sequencing identified a probable pathogen in 10% culture-negative specimens. Conclusion 16S rRNA PCR/sequencing can play a role in the diagnostic evaluation of patients with culture-negative infections, especially those with cardiovascular infections.
A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus
Venkatesulu, Bhanu Prasad , Chandrasekar, Viveksandeep Thoguluva , Girdhar, Prashanth, Advani, Pragati , Sharma, Amrish, Elumalai, Thiraviyam , Hsieh, Cheng‐En , Elghazawy, Hagar , Verma, Vivek , Krishnan, Sunil , Elghazawy, Hagar I , Krishnan, Sunil , Hsieh, Rodney Cheng-En

Mayo Clinic

JNCI Cancer Spectrum | February 20, 2021 | Volume: 5 | Issue: 2 | Pages: No page available

10.1093/jncics/pkaa102 | PMID 33875976 Get It

Abstract Background Cancer patients with coronavirus disease 2019 (COVID-19) have been reported to have double the case fatality rate of the general population. Methods A systematic search of PubMed, Embase, and Cochrane Central was done for studies on cancer patients with COVID-19. Pooled proportions were calculated for categorical variables. Odds ratio (OR) and forest plots (random-effects model) were constructed for both primary and secondary outcomes. Results This systematic review of 38 studies and meta-analysis of 181 323 patients from 26 studies included 23 736 cancer patients. Our meta-analysis shows that cancer patients with COVID-19 have a higher likelihood of death (n = 165 980, OR = 2.54, 95% confidence interval [CI] = 1.47 to 4.42), which was largely driven by mortality among patients in China. Cancer patients were more likely to be intubated. Among cancer subtypes, the mortality was highest in hematological malignancies (n = 878, OR = 2.39, 95% CI = 1.17 to 4.87) followed by lung cancer (n = 646, OR = 1.83, 95% CI = 1.00 to 3.37). There was no association between receipt of a particular type of oncologic therapy and mortality. Our study showed that cancer patients affected by COVID-19 are a decade older than the normal population and have a higher proportion of comorbidities. There was insufficient data to assess the association of COVID-19–directed therapy and survival outcomes in cancer patients. Conclusion Cancer patients with COVID-19 disease are at increased risk of mortality and morbidity. A more nuanced understanding of the interaction between cancer-directed therapies and COVID-19–directed therapies is needed. This will require uniform prospective recording of data, possibly in multi-institutional registry databases.